Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Huntsman

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
Acta Gastroenterologica Latinoamericana|October 25, 2007
[Hereditary diffuse gastric cancer (HDGC): presentation of a family with a new mutation of the CDH1 gene]Fernando Van Domselaar, Daniel Correa, Carlos Vaccaro, et al.
Molecular Cancer|January 9, 2008
Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell linesFaisal M Fadlelmola, Minglong Zhou, Ronald J de Leeuw, et al.
Academic Pathology|February 21, 2025
From good to great: The journey of sustained academic improvement of a university department of pathology and laboratory medicineZu-Hua Gao, Genevieve McMillan, Cheryl Wellington, et al.
Annals of Surgical Oncology|November 23, 2006
Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatmentSam M Wiseman, Hamid Masoudi, Paddy Niblock, et al.
BMC Cancer|June 6, 2025
Risk-reducing salpingectomy: considerations from an OBGYN perspectiveAlexandra Lukey, A Fuchsia Howard, Alice J Mei, et al.
Histopathology|November 7, 2013
A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovaryStefan Kommoss, Cyril Blake Gilks, Roland Penzel, et al.
The American Journal of Surgical Pathology|October 3, 2008
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovaryMartin Köbel, Steve E Kalloger, Jon Carrick, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 14, 2002
Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistryForrest D Hsu, Torsten O Nielsen, Abdulmohsen Alkushi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcomeChristopher B Moeder, Jennifer M Giltnane, Malini Harigopal, et al.
Breast Cancer Research : BCR|October 18, 2008
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypesGolareh Habibi, Samuel Leung, Jennifer H Law, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
Acta Gastroenterologica Latinoamericana|October 25, 2007
[Hereditary diffuse gastric cancer (HDGC): presentation of a family with a new mutation of the CDH1 gene]Fernando Van Domselaar, Daniel Correa, Carlos Vaccaro, et al.
Molecular Cancer|January 9, 2008
Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell linesFaisal M Fadlelmola, Minglong Zhou, Ronald J de Leeuw, et al.
Academic Pathology|February 21, 2025
From good to great: The journey of sustained academic improvement of a university department of pathology and laboratory medicineZu-Hua Gao, Genevieve McMillan, Cheryl Wellington, et al.
Annals of Surgical Oncology|November 23, 2006
Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatmentSam M Wiseman, Hamid Masoudi, Paddy Niblock, et al.
BMC Cancer|June 6, 2025
Risk-reducing salpingectomy: considerations from an OBGYN perspectiveAlexandra Lukey, A Fuchsia Howard, Alice J Mei, et al.
Histopathology|November 7, 2013
A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovaryStefan Kommoss, Cyril Blake Gilks, Roland Penzel, et al.
The American Journal of Surgical Pathology|October 3, 2008
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovaryMartin Köbel, Steve E Kalloger, Jon Carrick, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 14, 2002
Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistryForrest D Hsu, Torsten O Nielsen, Abdulmohsen Alkushi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcomeChristopher B Moeder, Jennifer M Giltnane, Malini Harigopal, et al.
Breast Cancer Research : BCR|October 18, 2008
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypesGolareh Habibi, Samuel Leung, Jennifer H Law, et al.
Pageof 15